LAVA Medtech Acquisition Corp.
| IPO Proceeds, $M | $115.00M |
|---|---|
| IPO Date | Oct 27, 2021 |
| CEO | Anthony Natale |
| Left Lead | RBC Capital Markets |
| IPO Cash in Trust | 102.5% |
| SPAC Tenor | 18 months |
| IPO Sector |
Healthcare
Innovative, development- or early commercial-stage companies focused on clinically-impactful and high growth opportunities within medical devices, diagnostics, and digital health |
| IPO Geography | US/Canada |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Apr 25, 2023 |
| Closing Date | May 15, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on LAVA Medtech Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 10 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Anthony Natale | Chief Executive Officer and Director | |
| Richard Emmitt | Chairman and Director | |
| Gerry Brunk | President and Director | |
| Daniel Hetu | Executive Vice President | |
| Vasco Larcina | Chief Financial Officer | |
| Peter van der Velden | Director | |
| Fritz A. LaPorte | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| RBC Capital Markets | BR | 10,000,000 | units |
| 10,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Oct 1, 2021 | Initial S-1 |
| Oct 26, 2021 |
PR announcing pricing of $100mm IPO
Sign In to view filing content. |
| Oct 28, 2021 | 424B4 IPO Prospectus |
| Oct 29, 2021 |
PR announcing full over-allotment exercise
Sign In to view filing content. |
| Dec 16, 2021 |
8-K announcing separate trading of common stock and warrants
Sign In to view filing content. |
| Mar 27, 2023 |
PRE14A Preliminary Proxy for charter extension meeting
Sign In to view filing content. |
| Apr 10, 2023 |
DEF14A Definitive Proxy for charter extension meeting
Sign In to view filing content. |
| Apr 18, 2023 |
8-K announcing clarification regarding excise tax and conversion of sponsor shares
Sign In to view filing content. |
| May 1, 2023 |
8-K announcing liquidation and redemption of all public shares
Sign In to view filing content. |
| May 10, 2023 |
8-K with redemption rate and liquidation timeline
Sign In to view filing content. |